Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Molecular targeted therapies for microscopic polyangiitis and granulomatosis with polyangiitis.

Harigai M, Tsutsumino M, Takada H, Nagasaka K.

Korean J Intern Med. 2019 Jan 9. doi: 10.3904/kjim.2018.366. [Epub ahead of print]

2.

Vasculitis research: Current trends and future perspectives.

Misra DP, Naidu GSRSNK, Agarwal V, Sharma A.

Int J Rheum Dis. 2018 Aug 30. doi: 10.1111/1756-185X.13370. [Epub ahead of print]

PMID:
30168260
3.

Orthosteric and allosteric action of the C5a receptor antagonists.

Liu H, Kim HR, Deepak RNVK, Wang L, Chung KY, Fan H, Wei Z, Zhang C.

Nat Struct Mol Biol. 2018 Jun;25(6):472-481. doi: 10.1038/s41594-018-0067-z. Epub 2018 Jun 4.

PMID:
29867214
4.

Antineutrophil cytoplasmic antibody associated vasculitides with renal involvement: Open challenges in the remission induction therapy.

Salvadori M, Tsalouchos A.

World J Nephrol. 2018 May 6;7(3):71-83. doi: 10.5527/wjn.v7.i3.71. Review.

5.

Avacopan in the treatment of ANCA-associated vasculitis.

Tesar V, Hruskova Z.

Expert Opin Investig Drugs. 2018 May;27(5):491-496. doi: 10.1080/13543784.2018.1472234. Epub 2018 May 8. Review.

PMID:
29718732
6.

[Novel trends in monitoring and therapy of ANCA associated vasculitides].

Bečvář R.

Vnitr Lek. 2018 Spring;64(2):164-168. Czech.

PMID:
29595281
7.

[Allergology and clinical immunology].

Coattrenec Y, Harr T, Chizzolini C, Jandus P.

Rev Med Suisse. 2018 Jan 10;14(588-589):15-18. French.

PMID:
29337441
8.

Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.

Jayne DRW, Bruchfeld AN, Harper L, Schaier M, Venning MC, Hamilton P, Burst V, Grundmann F, Jadoul M, Szombati I, Tesař V, Segelmark M, Potarca A, Schall TJ, Bekker P; CLEAR Study Group.

J Am Soc Nephrol. 2017 Sep;28(9):2756-2767. doi: 10.1681/ASN.2016111179. Epub 2017 Apr 11.

9.

Breaking down the complement system: a review and update on novel therapies.

Reddy YN, Siedlecki AM, Francis JM.

Curr Opin Nephrol Hypertens. 2017 Mar;26(2):123-128. doi: 10.1097/MNH.0000000000000305. Review.

PMID:
27977428
10.

Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study.

Bekker P, Dairaghi D, Seitz L, Leleti M, Wang Y, Ertl L, Baumgart T, Shugarts S, Lohr L, Dang T, Miao S, Zeng Y, Fan P, Zhang P, Johnson D, Powers J, Jaen J, Charo I, Schall TJ.

PLoS One. 2016 Oct 21;11(10):e0164646. doi: 10.1371/journal.pone.0164646. eCollection 2016. Erratum in: PLoS One. 2019 Jan 4;14(1):e0210593.

Supplemental Content

Loading ...
Support Center